Treatment of Waldenstrom's Macroglobulinemia

First-Line Therapy

The National Comprehensive Cancer Network recommends zanubrutinib as a preferred regimen for treatment-naïve symptomatic patients, alongside chemoimmunotherapy combinations, with the choice depending on patient-specific factors 1
For patients with high IgM or hyperviscosity, bortezomib-containing regimens are preferred to avoid IgM flare 2
Patients with pre-existing neuropathy should avoid bortezomib and instead use zanubrutinib or bendamustine-rituximab 3
The European Society for Medical Oncology suggests that patients with cardiac risk factors may prefer zanubrutinib due to its lower atrial fibrillation rates compared to ibrutinib 4

For patients relapsing within 12 months of chemoimmunotherapy, BTK inhibitors, including zanubrutinib, are the treatment of choice 2
The International Workshop on Waldenstrom's Macroglobulinemia recommends BTK inhibitors for rituximab-refractory patients 5

The National Comprehensive Cancer Network suggests assessing urgency, cardiac history, neuropathy, and MYD88 status to guide treatment selection 2
Patients with MYD88 wild-type disease may derive minimal benefit from BTK inhibitors and should consider chemoimmunotherapy instead 5
The European Society for Medical Oncology recommends avoiding the combination of zanubrutinib with warfarin and instead using alternative anticoagulation strategies 4

The American Society of Clinical Oncology recommends monitoring for neutropenia and considering G-CSF support in patients receiving zanubrutinib 4
Zanubrutinib should be held 3-7 days before and after surgical procedures 4

The National Comprehensive Cancer Network (NCCN) designates zanubrutinib as a Category 1 preferred regimen for treatment-naïve symptomatic Waldenström's macroglobulinemia (WM) patients 6
Zanubrutinib demonstrates a particular advantage in patients with CXCR4 co-mutations, producing higher very good partial response rates and superior progression-free survival compared to ibrutinib 6
The MYD88 L265P mutation is present in >90% of WM patients and predicts an excellent response to BTK inhibitors 7

Zanubrutinib is a preferred first-line option with superior safety compared to ibrutinib, particularly regarding cardiac toxicity, though it carries a higher neutropenia risk 6
Zanubrutinib demonstrates a 4-fold reduction in atrial fibrillation compared to ibrutinib, making it strongly preferred for patients with cardiac risk factors 6
Zanubrutinib carries a 2-fold higher neutropenia risk, with any grade neutropenia in 29% versus 13% with ibrutinib, and grade ≥3 neutropenia in 20% versus 8% 6

Confirm MYD88 mutation status before initiating BTK inhibitor therapy, as wild-type patients show no benefit 8
Assess CXCR4 mutation status, as co-mutation predicts delayed but still excellent response to zanubrutinib 6
Evaluate cardiac history, as zanubrutinib is strongly preferred over ibrutinib in patients with atrial fibrillation risk factors 6